The REMAP study aims to follow a cohort of 400 patients in around ten sleep centers in France and to collect clinical routine data. The objectives of this study are to investigate the effects of one-year management of OSA by CPAP or MAD on sleep architecture defined by objective macro and micro sleep architecture parameters using a sleep test device. sleep connected at home, to assess the quality of sleep and the quality of life reported by patients. The study will also allow us to define predictive factors for improving sleep quality during OSA treatment.

Inclusion Criteria:

• Patient already included in the SunSAS study (No. ID/RCB: 2021-A01827-34) or Patient who has undergone polygraphy or polysomnography eligible for treatment with CPAP or MAD in the context of OSA.
• Patient with a sleep test performed with the Sunrise device
• Men or Women from 18 to 80 years old
• Patient with OSAS eligible for CPAP or MAD therapy
• Affiliated patient or beneficiary of a social security scheme
• Signed informed consent

Exclusion Criteria:

• Patient previously treated for OSAS by CPAP or MAD during the last five years
• Patient with COPD or other respiratory diseases.
• Patient with contraindications to PPC or MAD therapy
• Patient with unstable heart disease or New York Heart Association class III or IV heart failure
• Patient unable to complete the study

Patients will be recruited based on scheduled appointments at the various centers that participate in the SunSAS clinical trial and are diagnosed and managed for their OSA in accordance with standard practice.